Oruka Therapeutics (ORKA) Accounts Payables (2010 - 2026)
Oruka Therapeutics' quarterly Accounts Payables came in at $3.7 million in Q1 2026, up 3.3% year-on-year from $3.5 million in Q1 2025, and down 11.87% quarter-over-quarter from $4.2 million in Q4 2025.
Oruka Therapeutics has reported Accounts Payables for 17 years, with the latest figure at $3.7 million in Q1 2026.
- For the quarter ending Q1 2026, Accounts Payables rose 3.3% year-over-year to $3.7 million; the trailing twelve-month figure through Mar 2026 stood at $3.7 million (up 3.3% YoY), and the FY2025 full-year result was $4.2 million, up 20.02% from the prior year.
- Accounts Payables for Q1 2026 stood at $3.7 million, down from $4.2 million in the prior quarter.
- The five-year high for Accounts Payables was $4.7 million in Q2 2025, with the low at $241000.0 in Q2 2023.
- Average Accounts Payables over 5 years is $1.7 million, with a median of $1.0 million recorded in 2022.
- Year-over-year, Accounts Payables sank 78.29% in 2023 and soared 856.35% in 2024.
- Tracing ORKA's Accounts Payables over 5 years: stood at $334000.0 in 2022, then increased by 8.38% to $362000.0 in 2023, then soared by 856.35% to $3.5 million in 2024, then increased by 20.02% to $4.2 million in 2025, then slipped by 11.87% to $3.7 million in 2026.
- The last three Accounts Payables figures came in at $3.7 million (Q1 2026), $4.2 million (Q4 2025), and $2.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 8.64 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Oruka Therapeutics | 3.04 Bn | 2.65 Bn | - | 3.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.66 Mn |
| Dec 31, 2025 | 4.16 Mn |
| Sep 30, 2025 | 2.21 Mn |
| Jun 30, 2025 | 4.66 Mn |
| Mar 31, 2025 | 3.55 Mn |
| Dec 31, 2024 | 3.46 Mn |
| Sep 30, 2024 | 2.15 Mn |
| Jun 30, 2024 | 571,000.00 |
| Mar 31, 2024 | 529,000.00 |
| Dec 31, 2023 | 362,000.00 |
| Sep 30, 2023 | 322,000.00 |
| Jun 30, 2023 | 241,000.00 |
| Mar 31, 2023 | 366,000.00 |
| Dec 31, 2022 | 334,000.00 |
| Sep 30, 2022 | 593,000.00 |
| Jun 30, 2022 | 1.11 Mn |
| Mar 31, 2022 | 1.01 Mn |
| Dec 31, 2021 | 1.12 Mn |
| Sep 30, 2021 | 1.13 Mn |
| Jun 30, 2021 | 2.19 Mn |
| Mar 31, 2021 | 1.58 Mn |
| Dec 31, 2020 | 1.77 Mn |
| Sep 30, 2020 | 761,000.00 |
| Jun 30, 2020 | 576,000.00 |
| Mar 31, 2020 | 167,000.00 |
| Dec 31, 2019 | 418,000.00 |
| Sep 30, 2019 | 135,000.00 |
| Jun 30, 2019 | 254,000.00 |
| Mar 31, 2019 | 260,000.00 |
| Dec 31, 2018 | 230,000.00 |
| Sep 30, 2018 | 217,000.00 |
| Jun 30, 2018 | 406,000.00 |
| Mar 31, 2018 | 772,000.00 |
| Dec 31, 2017 | 622,000.00 |
| Sep 30, 2017 | 1.24 Mn |
| Jun 30, 2017 | 1.07 Mn |
| Mar 31, 2017 | 980,000.00 |
| Dec 31, 2016 | 1.21 Mn |
| Sep 30, 2016 | 1.14 Mn |
| Jun 30, 2016 | 760,000.00 |
| Mar 31, 2016 | 1.01 Mn |
| Dec 31, 2015 | 364,000.00 |
| Sep 30, 2015 | 647,000.00 |
| Jun 30, 2015 | 714,000.00 |
| Mar 31, 2015 | 651,000.00 |
| Dec 31, 2014 | 795,000.00 |
| Sep 30, 2014 | 365,000.00 |
| Jun 30, 2014 | 725,000.00 |
| Mar 31, 2014 | 552,000.00 |
| Dec 31, 2013 | 597,000.00 |
| Sep 30, 2013 | 447,000.00 |
| Jun 30, 2013 | 387,000.00 |
| Mar 31, 2013 | 377,000.00 |
| Dec 31, 2012 | 65,000.00 |
| Sep 30, 2012 | 119,000.00 |
| Jun 30, 2012 | 227,000.00 |
| Mar 31, 2012 | 126,000.00 |
| Dec 31, 2011 | 260,000.00 |
| Sep 30, 2011 | 284,000.00 |
| Jun 30, 2011 | 517,000.00 |
| Dec 31, 2010 | 388,000.00 |